Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition
Open Access
Abstract
Background: Over 90% pancreatic cancers harbour activating kirsten rat sarcoma viral oncogene homolog (KRAS)mutations. However, monotherapies targeting the KRAS vertical pathway, with recently developed KRAS inhibitors or rapidly accelerated fibrosarcoma (RAF)/MEK/ERK inhibitors, have demonstrated limited clinical benefit. Therefore, there is an urgent need to identify novel therapeutic targets and combination strategies with KRAS inhibition. Objective: This study aims to identify pharmaceutical targets whose inhibition suppresses pancreatic ductal adenocarcinoma (PDAC) or potentiates KRAS inhibition, focusing on molecular vulnerabilities specific to KRAS-mutant PDAC. Designs: We integrated genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 (CRISPR-associated Protein 9) dropout screens, large-scale genomic dependency datasets and pharmacological screens to identify molecular vulnerabilities in KRAS-mutant PDAC. Conditional knockout mouse models were used to assess the essentiality of candidate genes in pancreatic cancer. RNA sequencing, metabolomics/proteomics analysis and stable isotopic tracing were employed to investigate mechanisms underlying inosine monophosphate dehydrogenase 2 (IMPDH2) vulnerability. Additionally, proteolysis-targeting chimaera compounds targeting IMPDH2 were developed and evaluated in patient-derived organoid and xenograft models. Results: Integrated screens revealed de novo guanine nucleotide biosynthesis (DNGB) as a vulnerability in KRAS-mutant PDAC, with IMPDH2 being the critical gene. Unexpectedly, IMPDH2 expression and activity are not driven by the KRAS vertical pathway. Consequently, IMPDH2 inhibition induces irreversible guanine nucleotide depletion that cannot be compensated for by mutant KRAS. Inducing guanine nucleotide depletion via targeting IMPDH2 for degradation inhibits PDAC and augments KRAS inhibitor efficacy in vitro and in vivo. Conclusions: These findings provide a rationale for developing combination therapies targeting KRAS and DNGB, highlighting the potential of purine nucleotide imbalance as a biomarker to guide the application of these therapies.Keywords
Funding Information
- National Natural Science Foundation of China (82203434)
- National Natural Science Foundation of China (82473106)
- National Natural Science Foundation of China (82473391)
- Shanghai Municipal Science and Technology Major Project (YDZX20243100002003)
- China Post-doc Science Foundation (2021M690698)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0525500/2024ZD0525501/2024ZD0525505)
This publication has 61 references indexed in Scilit:
- De novo and salvage purine synthesis pathways across tissues and tumorsCell, 2024
- Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma ProgressionHepatology Communications, 2020
- KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismCancer Cell, 2018
- A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 ProfilesCell, 2017
- Defining a Cancer Dependency MapCell, 2017
- Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and MetastasisCell, 2015
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDHBiochemical and Biophysical Research Communications, 2012
- Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: Purification and characterization of inhibitor bindingBiochemical Pharmacology, 1995
- Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205)Life Sciences, 1994